Literature DB >> 11739336

Activins and inhibins in endocrine and other tumors.

G P Risbridger1, J F Schmitt, D M Robertson.   

Abstract

Inhibin and activin are members of the TGF beta superfamily of growth and differentiation factors. They were first identified as gonadal-derived regulators of pituitary FSH and were subsequently assigned multiple actions in a wide range of tissues. More recently, the inhibin alpha subunit was considered as a tumor suppressor based on functional studies employing transgenic mouse models. This review evaluates the functional and molecular evidence that the inhibin alpha subunit is a tumor suppressor in endocrine cancers. The evaluation highlights the discrepant results from the human and mouse studies, as well as the differences between endocrine tumor types. In addition, we examine the evidence that the activin-signaling pathway is tumor suppressive and identify organ-specific differences in the actions and putative roles of this pathway in endocrine tumors. In summary, there is a considerable body of evidence to support the role of inhibins and activins in endocrine-related tumors. Future studies will define the mechanisms by which inhibins and activins contribute to the process of initiation, promotion, or progression of endocrine-related cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739336     DOI: 10.1210/edrv.22.6.0450

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  40 in total

Review 1.  Nodal and Cripto-1: embryonic pattern formation genes involved in mammary gland development and tumorigenesis.

Authors:  Nicholas J Kenney; Heather B Adkins; Michele Sanicola
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-04       Impact factor: 2.673

2.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

3.  Uric acid: a modulator of prostate cells and activin sensitivity.

Authors:  Febbie Sangkop; Geeta Singh; Ely Rodrigues; Elspeth Gold; Andrew Bahn
Journal:  Mol Cell Biochem       Date:  2016-02-24       Impact factor: 3.396

Review 4.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

5.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

6.  Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle.

Authors:  Ioannis Mylonas; Udo Jeschke; Irmgard Wiest; Anna Hoeing; Julia Vogl; Naim Shabani; Christina Kuhn; Sandra Schulze; Markus S Kupka; Klaus Friese
Journal:  Histochem Cell Biol       Date:  2004-10-12       Impact factor: 4.304

Review 7.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Identification of proteins involved in neural progenitor cell targeting of gliomas.

Authors:  Karin Staflin; Thole Zuchner; Gabriella Honeth; Anna Darabi; Cecilia Lundberg
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.